BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28182990)

  • 21. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
    Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
    Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.
    Momose I; Watanabe T
    J Antibiot (Tokyo); 2017 May; 70(5):542-550. PubMed ID: 28196975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
    Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
    J Med Chem; 2014 Mar; 57(6):2726-35. PubMed ID: 24524217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
    Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
    J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome.
    Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D
    Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
    Lei M; Feng H; Wang C; Li H; Shi J; Wang J; Liu Z; Chen S; Hu S; Zhu Y
    Bioorg Med Chem; 2016 Jun; 24(11):2576-2588. PubMed ID: 27117691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Groll M; Berkers CR; Ploegh HL; Ovaa H
    Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
    Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
    Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Zhang J; Shen L; Wang J; Luo P; Hu Y
    Med Chem; 2014; 10(1):38-45. PubMed ID: 23676009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Zhu Y; Wu G; Zhu X; Ma Y; Zhao X; Li Y; Yuan Y; Yang J; Yu S; Shao F; Lei M
    J Med Chem; 2010 Dec; 53(24):8619-26. PubMed ID: 21077681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and biological evaluation of some novel naphthoquinone-glycine/β-alanine anilide derivatives as noncovalent proteasome inhibitors.
    Tatar I; Uysal S; Yilmaz S; Tarikogullari AH; Ballar Kirmizibayrak P; Soyer Z
    Chem Biol Drug Des; 2023 Jun; 101(6):1283-1298. PubMed ID: 36762979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
    Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
    Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
    Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
    J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
    Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
    J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of dipeptides as novel non-covalent 20S proteasome inhibitors.
    Yang YJ; Wang K; Yang Y; Lai FF; Chen XG; Xiao ZY
    J Asian Nat Prod Res; 2021 May; 23(5):436-451. PubMed ID: 33844614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
    Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
    Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
    Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
    Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.